Related references
Note: Only part of the references are listed.PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells
Henning Schulze-Bergkamen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
Monoclonal antibodies in therapy of solid tumors
David M. Heimann et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2007)
Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
Y. Kawaguchi et al.
BRITISH JOURNAL OF CANCER (2007)
Recent developments in colorectal cancer treatment by monoclonal antibodies
Dominique Arsene et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2006)
Expression and release of HLA-E by melanoma cells and melanocytes: Potential impact on the response of cytotoxic effector cells
Laurent Derre et al.
JOURNAL OF IMMUNOLOGY (2006)
Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward
Gary J. Kelloff et al.
CLINICAL CANCER RESEARCH (2006)
American Cancer Society guidelines for the early detection of cancer, 2006
RA Smith et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2006)
Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies
A Iannello et al.
CANCER AND METASTASIS REVIEWS (2005)
Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft
FR Luo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: Implications for immune escape in vivo
J Wischhusen et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Induction of histone acetylation and inhibition of growth by phenyl alkanoic acids and structurally related molecules
MA Lea et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Increase in the ratio of mitochondrial Bax/Bcl-XL induces Bax activation in human leukemic K562 cell line
FT Liu et al.
APOPTOSIS (2004)
The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors
CA Ritter et al.
SEMINARS IN ONCOLOGY (2003)
Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody
BL Liu et al.
ONCOGENE (2001)
Share Paper
